MediWound Initiates U.S. Phase 2 Adaptive Design Study of EscharEx® for Treatment of Venous Leg Ulcers

NEXT STORY
HTG Molecular Diagnostics to Host Key Opinion Leader Meeting on the Future of Precision Medicine
PREV STORY
Myriad Genetics to Present Multiple Studies on Breast Cancer at the 2019 San Antonio Breast Cancer Symposium
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Sorrento Reports Positive Initial Result in Dosing of First Enbrel-Non-Responding Rheumatoid Arthritis Patient With the Sofusa® Lymphatic Drug Delivery Device

author_avatar
NASDAQ Market News

Calithera Achieves Positive Topline Results in Randomized Phase 2 ENTRATA Study of Telaglenastat with Everolimus in Renal Cell Carcinoma

author_avatar
NASDAQ Market News

Biocartis Group NV: Biocartis Obtains Exclusive Worldwide License Rights for EGFR Ectodomain Mutations Determining Response to Targeted Colorectal Cancer Therapy

PRESS RELEASE: 28 August 2018, 07:00 CEST Biocartis Obtains Exclusive Worldwide License Rights for ...

author_avatar
NASDAQ Market News